Who is on it, and how far along Every drug ChEMBL records acting on TIGIT, by the furthest stage it has reached for any use, coloured by modality.
How to read this Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.
Phase 34 Tiragolumab Tiragolumab SponsorRoche ModalityAntibody ActionInhibitor Open trials23 Domvanalimab Domvanalimab SponsorGilead Sciences ModalityAntibody ActionInhibitor Open trials13 Vibostolimab Vibostolimab SponsorMerck & Co. (MSD) ModalityAntibody ActionAntagonist Open trials5 Ociperlimab Ociperlimab SponsorBeOne Medicines ModalityAntibody ActionInhibitor Open trials0 Phase 21 Etigilimab Etigilimab SponsorMereo BioPharma ModalityAntibody ActionInhibitor Open trials1 Phase 12 ASP-8374 ASP-8374 SponsorAstellas Pharma ModalityOther ActionAntagonist Open trials0 IBI-939 IBI-939 SponsorInnovent Biologics (Suzhou) Co. Ltd. ModalityOther ActionInhibitor Open trials0
Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials. 5 of 7 act as: T-cell immunoreceptor with Ig and ITIM domains inhibitor; the rest name their own mechanism. The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 22 in all, from ClinicalTrials.gov. Trial Drug Phase Status Lead sponsor First posted Radiotherapy Plus Putelimab and Vibostolimab for Advanced Anal Squamous Cell Carcinoma Vibostolimab Phase 2 Not yet recruiting Fudan University Nov 13, 2026 TACE Combined With Tislelizumab, Lenvatinib, and Carvedilol for Unresectable HCC With Cirrhotic Portal Hypertension Tiragolumab Phase 2 Not yet recruiting Tongji Hospital Jan 20, 2026 Trial of FOLFIRI + Zimberelimab + Domvanalimab vs FOLFIRI With a Hybrid Synthetic Control Arm in Second Line Treatment of Neuroendocrine Carcinoma of Gastro-enteropancreatic or Unknown Origin (REWENEC 01) Domvanalimab Phase 2 Not yet recruiting Hospices Civils de Lyon Jan 13, 2026 IMMUNORARE5: A National Platform of 5 Academic Phase II Trials Coordinated by Lyon University Hospital to Assess the Safety and the Efficacy of the IMMUNOtherapy With Domvanalimab + Zimberelimab Combination in Patients With Advanced RARE Cancers Domvanalimab Phase 2 Active, not recruiting Hospices Civils de Lyon Jan 24, 2025 Phase I/Ib Trial of TIraGolumab, AtEzolizumab, and RadScopal Radiation in Patients With Advanced Solid Malignancies (TIGER) Tiragolumab Phase 1 Active, not recruiting M.D. Anderson Cancer Center Jan 6, 2025 A Phase 2 Clinical Trial Evaluating the Efficacy and Safety of Dual Immune Checkpoint Inhibition With Anti-PD-L1 (Atezolizumab) and Anti-TIGIT (Tiragolumab) in Cancer of Unknown Primary Tiragolumab Phase 2 Active, not recruiting M.D. Anderson Cancer Center Dec 31, 2024 Study of Novel Treatment Combination Therapies in Participants With Head and Neck Squamous Cell Carcinoma Regardless of PD-L1 Expression Status; Substudy-01 Domvanalimab Phase 2 Active, not recruiting Gilead Sciences Dec 11, 2024 NOvel Immunotherapy Strategies for Advanced Triple Negative Breast Cancer (TNBC) Patients: TONIC-3 Trial Tiragolumab Phase 2 Recruiting The Netherlands Cancer Institute Apr 2, 2024 Tiragolumab, Atezolizumab and Chemotherapy in Triple Negative Breast Cancer Tiragolumab Phase 2 Active, not recruiting Institut Curie Dec 18, 2023 PeRioperative Immunotherapy Combined With Sacituzumab Govitecan in Muscle Invasive blAdder Cancer Domvanalimab Phase 2 Active, not recruiting Fundación para el Progreso de la Oncología en Cantabria Nov 15, 2023 Tiragolumab and Atezolizumab in Advanced Pan-cancer Patients Tiragolumab Phase 2 Active, not recruiting Omico Aug 22, 2023 A Study Evaluating Atezolizumab and Bevacizumab, With or Without Tiragolumab, in Participants With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma (HCC) (IMbrave152) Tiragolumab Phase 3 Active, not recruiting Hoffmann-La Roche Jun 15, 2023 A Rollover Study for Participants Previously Enrolled in a Genentech and/or F. Hoffman-La Roche Sponsored Study Tiragolumab Phase 3 Recruiting Hoffmann-La Roche May 17, 2023 A Study of Efficacy and Safety of Pembrolizumab Plus Enfortumab Vedotin (EV) +/- Investigational Agents in First-Line Metastatic Urothelial Carcinoma (mUC) (MK-3475-04B/KEYMAKER-U04) Vibostolimab Phase 1 / Phase 2 Active, not recruiting Merck Sharp & Dohme LLC May 6, 2023 Domvanalimab and Zimberelimab in Advanced Liver Cancers Domvanalimab Phase 2 Active, not recruiting University of Texas Southwestern Medical Center Feb 13, 2023 EON: A Single-arm Phase II Study of Etigilimab (OMP-313M32) in Combination With Checkpoint Inhibition (Nivolumab) in Patients With Platinum-resistant, Recurrent Epithelial Ovarian Cancer Etigilimab Phase 2 Active, not recruiting M.D. Anderson Cancer Center Feb 6, 2023 Study With Various Immunotherapy Treatments in Participants With Lung Cancer Domvanalimab Phase 2 Active, not recruiting Gilead Sciences Jan 9, 2023 Study of Novel Treatment Combinations in Patients With Lung Cancer Domvanalimab Phase 2 Active, not recruiting Gilead Sciences Dec 1, 2022 Zimberelimab and Domvanalimab in Combination With Chemotherapy Versus Pembrolizumab With Chemotherapy in Patients With Untreated Metastatic Non-Small Cell Lung Cancer Domvanalimab Phase 3 Active, not recruiting Gilead Sciences Aug 16, 2022 Pembrolizumab/Vibostolimab (MK-7684A) or Atezolizumab in Combination With Chemotherapy in First Line Treatment of Extensive-Stage Small Cell Lung Cancer (MK-7684A-008/KEYVIBE-008) Vibostolimab Phase 3 Active, not recruiting Merck Sharp & Dohme LLC Feb 4, 2022 KEYMAKER-U01 Substudy 01A: Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Chemotherapy When Used With Investigational Agents in Treatment-naïve Participants With Stage IV Non-small Cell Lung Cancer (NSCLC) (MK-3475-01A/KEYMAKER-U01A) Vibostolimab Phase 1 / Phase 2 Recruiting Merck Sharp & Dohme LLC Nov 15, 2019 Study of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (MK-3475-365/KEYNOTE-365) Vibostolimab Phase 1 / Phase 2 Active, not recruiting Merck Sharp & Dohme LLC Aug 10, 2016
Show all 22Diseases most associated with it Open Targets association score, 0 to 1; all associations Non-small cell lung carcinoma 0.42 Non-small cell lung carcinoma Value0.42 Small cell lung carcinoma 0.38 Small cell lung carcinoma Value0.38 Esophageal squamous cell carcinoma 0.35 Esophageal squamous cell carcinoma Value0.35 Neurodegenerative disease 0.33 Neurodegenerative disease Value0.33 Melanoma 0.32 Melanoma Value0.32 Open Hepatocellular carcinoma 0.32 Hepatocellular carcinoma Value0.32 Open Cancer 0.31 Cancer Value0.31 Gastric adenocarcinoma 0.29 Gastric adenocarcinoma Value0.29 Gastroesophageal junction adenocarcinoma 0.29 Gastroesophageal junction adenocarcinoma Value0.29 Lung cancer 0.29 Lung cancer Value0.29 Open Esophageal adenocarcinoma 0.28 Esophageal adenocarcinoma Value0.28 Obesity disorder 0.24 Obesity disorder Value0.24 Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL4630878 , ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov , checked daily; this page as of 2026-11-21. Gene name, function (UniProt Q495A1 , CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets